as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹3,594.1
Change
+56.2 (1.59%)
Open
₹3,524.2
Prev. Close
₹3,537.9
Day High
₹3,625.0
Day Low
₹3,510.3
Volume Analysis
Traded
97,623
Delivered
59,594
Delivery %
61.05%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (26.0%)
- •Strong operating margin (25.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (3)
- •Strong 3-year EPS growth (145.2%)
- •Strong 3-year revenue growth (16.8%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹3,757.34 | ₹3,691.17 | ₹3,642.64 | ₹3,576.47 | ₹3,527.94 | ₹3,461.77 | ₹3,413.24 |
| Fibonacci | ₹3,691.17 | ₹3,647.35 | ₹3,620.29 | ₹3,576.47 | ₹3,532.65 | ₹3,505.59 | ₹3,461.77 |
| Camarilla | ₹3,625.64 | ₹3,615.13 | ₹3,604.61 | ₹3,576.47 | ₹3,583.59 | ₹3,573.07 | ₹3,562.56 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+28.4%
1 Week
+1.94%
1 Month
+3.94%
3 Months
-2.13%
6 Months
+22.62%
1 Year
+52.13%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹824.88
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
23.33%
Net margin 12.8% × asset turnover 0.81x × equity multiplier 2.25x
Company Overview
Sector
Chemicals
Market Cap
₹14,040 Cr
P/E (TTM)
40.1
ROE
26.0%
Book Value
₹361.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Privi Speciality Che Ltd holds up reasonably well on TopFund's composite fundamentals check within the Chemicals sector, at 71/100. The strongest factor is Liquidity (91/100), while Valuation (7/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (26.0%); strong operating margin (25.0%); promoter holding is falling. Strong 3-year EPS growth (145.2%).
TopFund Score — Fundamentals Quality
71/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 26.8% CAGR over last 5 years
- −Stock is trading at 9.95 times its book value
- −Promoter holding has decreased over last 3 years: -13.4%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Newspaper Publication of Notice Convening Meeting of Equity Shareholders (Meeting) of the Company Convened in accordance with the order of the Hon''ble National Company Law …
Trading window closes from October 1, 2026 until 48 hours after Q2 FY2026 results.
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR), Regulations 2015.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 409 | 455 | 404 | 484 | 464 | 533 | 491 | 614 | 559 | 679 | 605 | 722 | 666 |
| Expenses + | 354 | 366 | 314 | 393 | 370 | 423 | 378 | 481 | 427 | 497 | 453 | 541 | 514 |
| Operating Profit | 55 | 89 | 90 | 91 | 94 | 110 | 113 | 133 | 132 | 182 | 151 | 180 | 152 |
| OPM % | 13.0% | 20.0% | 22.0% | 19.0% | 20.0% | 21.0% | 23.0% | 22.0% | 24.0% | 27.0% | 25.0% | 25.0% | 23.0% |
| Other Income + | 6 | 7 | 6 | 8 | 3 | 4 | 2 | 15 | 9 | 0 | 7 | 4 | 15 |
| Interest | 24 | 25 | 24 | 25 | 22 | 22 | 22 | 23 | 24 | 21 | 19 | 18 | 17 |
| Depreciation | 31 | 31 | 32 | 30 | 32 | 32 | 32 | 35 | 36 | 36 | 36 | 36 | 37 |
| Profit before tax | 6 | 40 | 39 | 44 | 43 | 61 | 61 | 90 | 81 | 125 | 104 | 130 | 113 |
| Tax % | 30.0% | 25.0% | 26.0% | 28.0% | 27.0% | 26.0% | 27.0% | 29.0% | 29.0% | 28.0% | 28.0% | 27.0% | 27.0% |
| Net Profit + | 5 | 30 | 29 | 32 | 31 | 45 | 44 | 64 | 58 | 90 | 75 | 94 | 83 |
| EPS in Rs | 1 | 8 | 7 | 8 | 8 | 11 | 11 | 17 | 16 | 24 | 20 | 24 | 22 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 597 | 1,024 | 1,341 | 1,631 | 1,277 | 1,404 | 1,608 | 1,752 | 2,101 | 2,564 | 2,671 |
| Expenses + | 525 | 894 | 1,128 | 1,362 | 1,067 | 1,209 | 1,420 | 1,423 | 1,643 | 1,912 | 2,005 |
| Operating Profit | 72 | 130 | 213 | 268 | 210 | 195 | 188 | 329 | 458 | 651 | 666 |
| OPM % | 12.0% | 13.0% | 16.0% | 16.0% | 16.0% | 14.0% | 12.0% | 19.0% | 22.0% | 25.0% | 25.0% |
| Other Income + | 10 | 16 | 14 | 66 | 43 | 38 | 21 | 26 | 20 | 19 | 26 |
| Interest | 20 | 24 | 29 | 41 | 24 | 25 | 70 | 102 | 92 | 87 | 75 |
| Depreciation | 27 | 43 | 47 | 63 | 71 | 75 | 108 | 123 | 132 | 144 | 145 |
| Profit before tax | 36 | 79 | 152 | 231 | 158 | 133 | 31 | 130 | 255 | 440 | 472 |
| Tax % | 24.0% | 32.0% | 38.0% | 24.0% | 26.0% | 27.0% | 31.0% | 27.0% | 27.0% | 28.0% | — |
| Net Profit + | 27 | 53 | 94 | 176 | 117 | 97 | 21 | 95 | 185 | 317 | 342 |
| EPS in Rs | 7 | 14 | 24 | 45 | 30 | 25 | 6 | 24 | 48 | 84 | 89 |
| Dividend Payout % | 14.0% | 11.0% | 10.0% | 3.0% | 7.0% | 8.0% | 0.0% | 8.0% | 10.0% | 12.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 406 | 451 | 537 | 702 | 683 | 773 | 790 | 885 | 1,064 | 1,373 |
| Borrowings + | 321 | 330 | 491 | 569 | 537 | 933 | 1,079 | 1,008 | 1,143 | 1,021 |
| Other Liabilities + | 174 | 235 | 359 | 294 | 281 | 431 | 483 | 410 | 544 | 736 |
| Total Liabilities | 939 | 1,053 | 1,426 | 1,604 | 1,540 | 2,176 | 2,391 | 2,343 | 2,791 | 3,170 |
| Fixed Assets + | 388 | 437 | 498 | 725 | 598 | 704 | 1,017 | 1,034 | 1,156 | 1,169 |
| CWIP | 24 | 49 | 95 | 40 | 175 | 373 | 100 | 99 | 141 | 314 |
| Investments | 1 | 3 | 0 | 1 | 0 | 12 | 7 | 40 | 8 | 54 |
| Other Assets + | 527 | 564 | 833 | 839 | 768 | 1,087 | 1,268 | 1,169 | 1,485 | 1,633 |
| Total Assets | 939 | 1,053 | 1,426 | 1,604 | 1,540 | 2,176 | 2,391 | 2,343 | 2,791 | 3,170 |
| Equity Capital | 38 | 38 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 17 | 107 | 21 | 247 | 172 | 5 | 49 | 354 | 281 | 550 |
| Cash from Investing Activity + | 80 | -81 | -139 | -206 | -242 | -321 | -133 | -180 | -294 | -358 |
| Cash from Financing Activity + | -89 | -20 | 122 | 27 | 0 | 333 | 72 | -171 | 39 | -198 |
| Net Cash Flow | 7 | 5 | 4 | 68 | -69 | 17 | -12 | 4 | 26 | -6 |
| CFO/OP | 49 | 96 | 24 | 120 | 101 | 19 | 33 | 116 | 77 | 102 |
| Free Cash Flow | 17 | 107 | 46 | 37 | -71 | -304 | -91 | 212 | -17 | 230 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 21.62% | 21.59% | 21.95% | 22.62% | 23.02% | 23.38% | 23.62% | 24.73% | 24.24% | 27.51% | 27.36% | 27.39% |
| Promoters | 74.05% | 74.05% | 74.05% | 74.05% | 74.05% | 74.05% | 74.05% | 69.89% | 69.89% | 60.6% | 60.6% | 60.6% |
| FII | 0.97% | 0.96% | 0.62% | 0.48% | 0.43% | 0.48% | 0.4% | 1.47% | 1.33% | 1.64% | 1.37% | 1.94% |
| DII | 3.37% | 3.39% | 3.37% | 2.84% | 2.49% | 2.09% | 1.95% | 3.9% | 4.55% | 10.25% | 10.67% | 10.07% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Chemicals — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Privi Speciality Che Ltd (this stock) | 14,040 | 40.1 | 9.96 | 26.0% |
| Anupam Rasayan India Ltd | 13,422 | 76.8 | 4.07 | 5.55% |
| Pcbl Chemical Limited | 13,362 | 50.5 | 3.33 | 5.56% |
| Vinati Organics Ltd | 12,506 | 27.9 | 3.95 | 14.9% |
| Basf India Ltd | 15,617 | 25.3 | 3.95 | 10.9% |
| Fine Organic Ind. Ltd. | 15,652 | 35.7 | 5.87 | 16.5% |
| Paradeep Phosphates Ltd | 16,148 | 14.9 | 2.37 | 16.2% |
Which Mutual Funds Hold Privi Speciality Che Ltd?
Frequently Asked Questions about Privi Speciality Che Ltd
Privi Speciality Che Ltd (PRIVISCL) closed at ₹3,594.1 on NSE on 25 September 2026, up 56.2 (1.59%) from the previous close.
Privi Speciality Che Ltd trades on the NSE (National Stock Exchange of India) under the symbol PRIVISCL.
Privi Speciality Che Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 40.1.
Privi Speciality Che Ltd has a dividend yield of 0.28%.
Privi Speciality Che Ltd's 52-week high is ₹3,785.0 and its 52-week low is ₹2,310.0.
Privi Speciality Che Ltd has a market capitalisation of ₹14,040 crore.
Privi Speciality Che Ltd has a TopFund Quality Score of 71/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Privi Speciality Che Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.